Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Relationship between EGFR Over-expression and Clinicopathologic Characteristics in Squamous Cell Carcinoma of the Esophagus: A Meta-analysis

  • Wang, Jun (Department of Radiation Oncology, the Fourth Hospital of HeBei Medical University) ;
  • Yu, Jin-Ming (Academy of Medical Sciences of Shandong, Key Laboratory of Radiation Oncology and Department of Radiation Oncology, Tumor Hospital of Shandong) ;
  • Jing, Shao-Wu (Department of Radiation Oncology, the Fourth Hospital of HeBei Medical University) ;
  • Guo, Yin (Department of Radiation Oncology, the Fourth Hospital of HeBei Medical University) ;
  • Wu, Ya-Jing (Department of Radiation Oncology, the Fourth Hospital of HeBei Medical University) ;
  • Li, Na (Department of Radiation Oncology, the Fourth Hospital of HeBei Medical University) ;
  • Jiao, Wen-Peng (Department of Radiation Oncology, the Fourth Hospital of HeBei Medical University) ;
  • Wang, Li (Department of Radiation Oncology, the Fourth Hospital of HeBei Medical University) ;
  • Zhang, Yan-Jun (Department of Radiation Oncology, the Fourth Hospital of HeBei Medical University)
  • Published : 2014.07.30
Download PDF
⟨ Previous Next ⟩

Abstract

Over-expression of epidermal growth factor receptor (EGFR) has been identified as a common feature associated with clinical outcome in many types of cancer, including squamous cell carcinoma of the oesophagus (SCCO). However, the clinical importance of EGFR over-expression in SCCO remains unsettled as conflicting results exist. Therefore we carried out the present meta-analysis of published studies for clarification. A total of 13 studies including 1, 150 patients were enrolled. EGFR over-expression was positive in 722 of these cases. With EGFR over-expression, patients had higher depth of invasion, vascular invasion, and poor prognosis. However, expression had no relation with degree of differentiation, histological grade, lymph node metastasis, clinical stage or lymphatic invasion. EGFR over-expression is probably a valuable predictor for the T stage, vascular invasion and OS, and it could be used as a poor prognosis indicator for the esophageal SCC patients. Targeting therapy to EFGR should be considered to the combined treatment in SCCO.

Keywords

References

  1. Abusail MS, Dirweesh AM, Salih RA, et al (2013). Expression of EGFR and p53 in head and neck tumors among Sudanese patients. Asian Pac J Cancer Prev, 14, 6415-8. https://doi.org/10.7314/APJCP.2013.14.11.6415
  2. Ando N, Ozawa S, Kitagawa Y, et al (2000). Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years. Ann Surg, 232, 225-32. https://doi.org/10.1097/00000658-200008000-00013
  3. Chen WC, Zhang SW, Zheng RS, et al (2011). Analysis of cancer incidence and death in cancer registration areas in 2007. China Cancer, 20, 162-9.
  4. Delektorskaya VV, Chemeris GY, Kononets PV, et al (2009). Clinical significance of hyperexpression of epidermal growth factor receptors (EGFR and HER-2) in esophageal squamous cell carcinoma. Bull Exp Biol Med, 148, 241-5. https://doi.org/10.1007/s10517-009-0659-z
  5. Fukai Y, Masuda N, Kato H, et al (2005). Correlation between laminin-5 gamma2 chain and epidermal growth factor receptor expression in esophageal squamous cell carcinomas. Oncology, 69, 71-80. https://doi.org/10.1159/000087477
  6. Gibault L, Metges JP, Conan-Charlet V, et al (2005). Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer. Br J Cancer, 93, 107-15. https://doi.org/10.1038/sj.bjc.6602625
  7. Hanawa M, Suzuki S, Dobashi Y, et al (2006). EGFR protein over-expression and gene amplification in squamous cell carcinomas of the esophagus. Int J Cancer, 118, 1173-80. https://doi.org/10.1002/ijc.21454
  8. Hoshino M, Fukui H, Ono Y, et al (2007). Nuclear expression of phosphorylated EGFR is associated with poor prognosis of patients with esophageal squamous cell carcinoma. Pathobiology, 74, 15-21. https://doi.org/10.1159/000101047
  9. Iihara K, Shiozaki H, Tahara H, et al (1993). Prognostic significance of transforming growth factor-alpha in human esophageal carcinoma. Cancer, 71, 2902-9. https://doi.org/10.1002/1097-0142(19930515)71:10<2902::AID-CNCR2820711004>3.0.CO;2-J
  10. Inada S, Koto T, Futami K, et al (1999). Evaluation of malignancy and the prognosis of esophageal cancer based on an immunohistochemical study (p53, E-cadherin, epidermal growth factor receptor). Surg Today, 29, 493-503. https://doi.org/10.1007/BF02482343
  11. Itakura Y, Sasano H, Shiga C, et al (1994). Epidermal growth factor receptor over-expression in esophageal carcinoma. Cancer, 74, 795-804. https://doi.org/10.1002/1097-0142(19940801)74:3<795::AID-CNCR2820740303>3.0.CO;2-I
  12. Lorenzen S, Schuster T, Porschen R, et al (2009). Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische onkologie. Ann Oncol, 20, 1667-73. https://doi.org/10.1093/annonc/mdp069
  13. Matkovic B, Juretic A, Separovic V, et al (2008). Immunohistochemical analysis of ER, PR, HER-2, CK 5/6, p63 and EGFR antigen expression in medullary breast cancer. Tumori, 94, 838-44.
  14. Molaei M, Pejhan S, Nayer BN, et al (2009). Human epidermal growth factor receptor-2 family in colorectal adenocarcinoma: correlation with survival and clinicopathological findings. Eur J Gastroenterol Hepatol, 21, 289-93. https://doi.org/10.1097/MEG.0b013e32830b82ba
  15. Mukaida H, Toi M, Hirai T, et al (1991). Clinical significance of the expression of epidermal growth factor and its receptor in esophageal cancer. Cancer, 68, 142-8. https://doi.org/10.1002/1097-0142(19910701)68:1<142::AID-CNCR2820680126>3.0.CO;2-X
  16. O-charoenrat P, Rhys-Evans PH, Archer DJ, et al (2002). C-erbB receptors in squamous cell carcinomas of the head and neck: clinical significance and correlation with matrix metalloproteinases and vascular endothelial growth factors. Oral Oncol, 38, 73-80. https://doi.org/10.1016/S1368-8375(01)00029-X
  17. Parmar MK, Torri V, Stewart L (1998). Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med, 17, 2815-34. https://doi.org/10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8
  18. Sarbia M, Ott N, Puhringer-Oppermann F, et al (2007). The predictive value of molecular markers (p53, EGFR, ATM, CHK2) in multimodally treated squamous cell carcinoma of the oesophagus. Br J Cancer, 97, 1404-8. https://doi.org/10.1038/sj.bjc.6604037
  19. Sunpaweravong P, Sunpaweravong S, Puttawibul P, et al (2005). Epidermal growth factor receptor and cyclin D1 are independently amplified and overexpressed in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol, 131, 111-9. https://doi.org/10.1007/s00432-004-0610-7
  20. Torzewski M, Sarbia M, Verreet P, et al (1997). The prognostic significance of epidermal growth factor receptor expression in squamous cell carcinomas of the oesophagus. Anticancer Res, 17, 3915-9.
  21. Woodburn JR (1999). The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther, 82, 241-50. https://doi.org/10.1016/S0163-7258(98)00045-X
  22. Yamamoto Y, Yamai H, Seike J, et al (2012). Prognosis of esophageal squamous cell carcinoma in patients positive for human epidermal growth factor receptor family can be improved by initial chemotherapy with docetaxel, fluorouracil, and cisplatin. Ann Surg Oncol, 19, 757-65. https://doi.org/10.1245/s10434-011-2071-y
  23. Yu WW, Guo YM, Zhu M, et al (2011). Clinicopathological and prognostic significance of EGFR over-expression in esophageal squamous cell carcinoma: a meta-analysis. Hepatogastroenterology, 58, 426-31.

Cited by

  1. Clinical Observation and Therapeutic Evaluation of Rh-endostatin Combined with DP Regimen in Treating Patients with Advanced Esophageal Cancer vol.15, pp.16, 2014, https://doi.org/10.7314/APJCP.2014.15.16.6565
  2. Systematic Analysis of Pemetrexed-based Chemoradiotherapy for Patients with Locally Advanced or Metastatic Esophageal Cancer vol.15, pp.19, 2014, https://doi.org/10.7314/APJCP.2014.15.19.8475
  3. Design, Synthesis, and Molecular Docking Studies of 2-(Furan-2-yl)quinazolin-4-one Derivatives as Potential Antiproliferative Agents vol.348, pp.7, 2015, https://doi.org/10.1002/ardp.201400468
  4. The prognostic significance of human epidermal growth factor receptor family protein expression in operable pancreatic cancer vol.16, pp.1, 2016, https://doi.org/10.1186/s12885-016-2889-6
  5. Kaempferol inhibits cell proliferation and glycolysis in esophagus squamous cell carcinoma via targeting EGFR signaling pathway vol.37, pp.8, 2016, https://doi.org/10.1007/s13277-016-4912-6
  6. GE11 peptide conjugated selenium nanoparticles for EGFR targeted oridonin delivery to achieve enhanced anticancer efficacy by inhibiting EGFR-mediated PI3K/AKT and Ras/Raf/MEK/ERK pathways vol.24, pp.1, 2017, https://doi.org/10.1080/10717544.2017.1386729
  7. Immunohistochemical prognostic markers of esophageal squamous cell carcinoma: a systematic review vol.36, pp.1, 2017, https://doi.org/10.1186/s40880-017-0232-5
  8. Resveratrol mediates cell cycle arrest and cell death in human esophageal squamous cell carcinoma by directly targeting the EGFR signaling pathway vol.13, pp.1, 2016, https://doi.org/10.3892/ol.2016.5391
  9. Excision repair cross-complementing group 1 (ERCC1) overexpression inhibits cell apoptosis and is associated with unfavorable prognosis of esophageal squamous cell carcinoma vol.97, pp.31, 2018, https://doi.org/10.1097/MD.0000000000011697